HIT Consultant November 11, 2024
What You Should Know:
– Oxford Cannabinoid Technologies (OCT) has announced a significant milestone in its drug discovery program: the successful “proof of concept” of its AI-enabled drug discovery asset.
– Developed in collaboration with New York-based tech consultancy Hypatia AI, this cutting-edge tool promises to accelerate OCT’s research and development of non-addictive pain medications.
Accelerating Drug Discovery with AI
Hypatia AI’s technology acts as an “endlessly resourceful research assistant,” leveraging large language models to analyze vast amounts of scientific literature and uncover hidden connections. This targeted approach allows OCT’s scientific team to:
- Enhance Efficiency: Spend less time searching for information and more time focused on discovery.
- Gain Deeper Insights: Uncover relationships and insights that may be...
Today's Sponsors
Today's Sponsor